

LCC's Expansion Boosted by new Head of Business Development

24th January 2023

LCC are delighted to welcome Anthony (Tony) Huxley as Head of Business Development. Tony takes over the department from LCC's CEO, Dr Paul Colbon, who has led the company's business development since cofounding LCC in 2014.

2022 was a year of strategic change and restructuring for LCC, with onshoring of all chemistry back in the UK as it moved to new facilities at The Heath science park in Runcorn. Major investments were made into the new labs, equipping them with software, automation and liquid handling for parallel synthesis and compound management, as well as expanding the chemistry team under the leadership of Mark Jones, who joined as Head of Chemistry in September.

Tony is an experienced drug hunter, medicinal chemist, leader and entrepreneur. 10 years as a medicinal chemist at GSK were followed by Tony cofounding a successful chemistry CRO in 2007, and then joined Redx as a project leader in 2013. After 3 years at Redx Anti-Infectives, Tony enjoyed 3 years as a research leader at Concept Life Sciences. Decades of leading medicinal chemistry projects and serving the sector in the CRO landscape mean that Tony has a great appreciation for how LCC adds strategic value to modern-day drug discovery.

Paul Colbon commented on Tony's appointment... "Tony's appointment is a real indicator of how the company has developed over recent years. He brings a wealth of medicinal chemistry knowledge into the wider team and helps me to keep to our customer-centric mission of providing value to clients' Hit-ID and LO campaigns. His energy is infectious and I can't wait to work with him."

Tony said "I'm delighted to join Paul and the LCC team at this exciting time in the company's journey. I am particularly looking forward to helping customers rapidly access structurally diverse, rarely exploited chiral chemical space via a number of products including building blocks, access to highly functionalised DEL synthons, covalent and non-covalent libraries. Alongside capabilities in Virtual Library design and rapid parallel synthesis, LCC is the perfect partner to accelerate the discovery and development of high-quality drugs for the ultimate benefit of our customers patients."